Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis

This publication has 19 references indexed in Scilit:

• The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study
  Atherosclerosis, 1998
• −455G/A Polymorphism of the β-Fibrinogen Gene is Associated With the Progression of Coronary Atherosclerosis in Symptomatic Men
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1998
• The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis
  New England Journal of Medicine, 1998
• Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression
  Journal of Biological Chemistry, 1996
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Effect of Pravastatin on Outcomes after Cardiac Transplantation
  New England Journal of Medicine, 1995
• Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.
  Heart, 1995
• Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
  Journal of Clinical Investigation, 1994
• Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
• Enhanced Expression of Vascular Matrix Metalloproteinases Induced In Vitro by Cytokines and in Regions of Human Atherosclerotic Lesions^a
  Annals of the New York Academy of Sciences, 1994